Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12 -15 at the Boston Convention and Exhibition Center. Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics.

“Target- and Resistance-Based Mechanistic Studies with Fluorocyclines TP-434 and TP-271”

"We are looking forward to sharing our data with clinicians and colleagues from around the world in 13 separate data presentations, ranging from bench to clinic," said Guy Macdonald, President and Chief Executive Officer of Tetraphase. "As demonstrated by the breadth of our TP-434 data at ICAAC, we believe that TP-434's unique advantages are further revealed as a potential first-line monotherapy capable of treating gram-negative pathogens while also having potent effects on a broad spectrum of other serious and multidrug-resistant 'superbug' pathogens."

The schedule and meeting location for the sessions, together with the abstract information, are listed below:

Sunday, Poster Summary Session 030, All New Antimicrobial Agents: 1:45 PM (Room 201A)

Tetraphase has been selected to present an oral summary highlighting key posters on TP-434 and providing an overview of data presented.

Sunday, Poster Session 002, Pharmacology of Oxazolidinones and Miscellaneous Antibacterial Agents: 11:30 AM-1:30 PM (Exhibit Hall B1)

Title: "Phase I Single and Multiple Ascending Dose Study of a Broad-Spectrum Fluorocycline, TP-434", Sutcliffe, et al., Abstract: A1-027/Poster Board 24

Title: "Population Pharmacokinetic Modeling of TP-434, a Novel Fluorocycline, Following Single and Multiple Dose Administration", Yue, et al., Abstract: A1-028/ Poster Board 25

Wednesday, Poster Session 247, New Oxazolidinones, Ketolides, and Tetracyclines: 9:00-11:00 AM (Exhibit Hall B1)

Title: "Fluorocyclines: A New Class of Broad-Spectrum Tetracyclines with Antibacterial Properties", Clark, et al., Abstract: F1-2155/Poster Board 174

Title: "TP-271, a Novel Oral Fluorocycline for Community-Acquired Respiratory and Biothreat Pathogens", Grossman, et al., Abstract: F1-2156/Poster Board 175

Title: "TP-434 is a Novel Broad-Spectrum Fluorocycline", Xiao, et al., Abstract: F1-2157/Poster Board 176

Title: "In Vitro Activity of Fluorocycline TP-434 against Panels of Recent Bacterial Clinical Isolates", Sutcliffe, et al., Abstract: F1-2158/Poster Board 177

Title: "In Vitro Activity of Fluorocyclines against Legionella pneumophilia", Dubois, et al., Abstract: F1-2159/Poster Board 178

Title: "Target- and Resistance-Based Mechanistic Studies with Fluorocyclines TP-434 and TP-271", Starosta, et al., Abstract: F1-2160/Poster Board 179

Title: "TP-434 is Highly Efficacious in Animal Models of Infection", Murphy, et al., Abstract: F1-2161/Poster Board 180

Title: "TP-434 is Metabolically Stable and Has Low Potential for Drug-Drug Interactions", Christ, et al., Abstract: F1- 2162/Poster Board 181

Title: "Pharmacokinetics of TP-434 in Mouse, Rat, Dog, Monkey and Chimpanzee", Ronn, et al., Abstract: F1-2163/Poster Board 182

Title: "Efficacy of Fluorocycline TP-434 in the Neutropenic Thigh Infection Model is Predicted by AUC/MIC", Weiss, et al., Abstract: F1-2164/Poster Board 183

SOURCE Tetraphase Pharmaceuticals, Inc.